Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
暂无分享,去创建一个
Hugues Dolgos | Johan Gabrielsson | Ulf Bredberg | Per-Göran Gillberg | Bert Benthem | Göran Duker | U. Bredberg | P. Gillberg | J. Gabrielsson | G. Duker | H. Dolgos | B. Benthem
[1] Lewis B. Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .
[2] F. Quimby,et al. The Clinical chemistry of laboratory animals , 1989 .
[3] T. Barrett,et al. Functional pharmacology: the drug discovery bottleneck? , 2004 .
[4] Malcolm Rowland,et al. Clinical pharmacokinetics : concepts and applications , 1989 .
[5] V. Alabaster,et al. The fall and rise of in vivo pharmacology. , 2002, Trends in pharmacological sciences.
[6] G. Levy,et al. Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.
[7] R. Copeland,et al. Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.
[8] L. Benet,et al. Changes in plasma protein binding have little clinical relevance , 2002, Clinical pharmacology and therapeutics.
[9] Johan Gabrielsson,et al. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2002 .
[10] G. Segre,et al. Kinetics of interaction between drugs and biological systems. , 1968, Il Farmaco; edizione scientifica.
[11] Terrence P. Kenakin,et al. A Pharmacologic Analysis of Drug-Receptor Interaction , 1987 .
[12] Varun Garg,et al. Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[13] V F Smolen,et al. Quantitative determination of drug bioavailability and biokinetic behavior from pharmacological data for ophthalmic and oral administrations of a mydriatic drug. , 1971, Journal of pharmaceutical sciences.
[14] M. Tabo,et al. Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization. , 2007, Journal of pharmacological and toxicological methods.
[15] W. H. Barr,et al. Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development , 1993, Springer US.
[16] W. Jusko,et al. Modeling of dose–response–time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles , 2000, Biopharmaceutics & drug disposition.
[17] G Levy,et al. Predicting Effective Drug Concentrations for Individual Patients , 1998, Clinical pharmacokinetics.
[18] Gerhard Levy,et al. The Case for Preclinical Pharmacodynamics , 1993 .
[19] G Levy,et al. Mechanism‐based pharmacodynamic modeling , 1994, Clinical pharmacology and therapeutics.
[20] F. Sams-Dodd. Target-based drug discovery: is something wrong? , 2005, Drug discovery today.